Jeffrey Flier on GLP-1 drug discovery Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration
Langmuir 30(30):91309138
These weaknesses allowed deletion or manipulation of electronic records and undermined the traceability required for CGMP decision-making
Most of our weight loss treatments are well-tolerated, but some patients may experience mild side effects such as nausea, headaches, or injection site discomfort
Key Benefits of Tesamorelin Targeted visceral fat reduction in the abdominal cavity Improved metabolic markers, including triglyceride levels and insulin sensitivity Enhanced cognition, sleep quality, and energy in individuals with GH deficiency Convenient once-daily injection Because visceral fat is linked to cardiovascular disease, insulin resistance, and type 2 diabetes, Tesamorelin plays a pivotal role in reducing cardiometabolic risk in affected populations
Le mdecin gnraliste est le premier interlocuteur
)
